» Articles » PMID: 34075063

High-sensitivity CRP May Be a Marker of HDL Dysfunction and Remodeling in Patients with Acute Coronary Syndrome

Overview
Journal Sci Rep
Specialty Science
Date 2021 Jun 2
PMID 34075063
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

In patients with coronary artery disease (CAD), further increasing the level of high-density lipoprotein (HDL) cholesterol (HDL-C) as an add-on to statins cannot reduce cardiovascular risk. And it has been reported that HDL functional metric-cholesterol efflux capacity (CEC) may be a better predictor of CAD risk than HDL-C. CEC measurement is time-consuming and not applicable in clinical settings. Thus, it is meaningful to explore an easily acquired index for evaluating CEC. Thirty-six CAD patients and sixty-one non-CAD controls were enrolled in this cross-sectional study. All CAD patients had acute coronary syndrome (ACS). CEC was measured using a [H] cholesterol loading Raw 264.7 cell model with apolipoprotein B-depleted plasma (a surrogate for HDL). Proton nuclear magnetic resonance (NMR) spectroscopy was used to assess HDL components and subclass distribution. CEC was significantly impaired in CAD patients (11.9 ± 2.3%) compared to controls (13.0 ± 2.2%, p = 0.022). In control group, CEC was positively correlated with enzymatically measured HDL-C levels (r = 0.358, p = 0.006) or with NMR-determined HDL-C levels (NMR-HDL-C, r = 0.416, p = 0.001). However, in CAD group, there was no significant correlation between CEC and HDL-C (r = 0.216, p = 0.206) or NMR-HDL-C (r = 0.065, p = 0.708). Instead, we found that the level of high-sensitivity C-reactive protein (hsCRP) was inversely associated with CEC (r = - 0.351, p = 0.036). Multiple regression analysis showed that the hsCRP level was associated with CEC after adjusting other cardiovascular risk factors and HDL-C, although the association would not reach significance if adjusting for multiple testing. NMR spectroscopy showed that HDL particles shifted to larger ones in patients with high hsCRP levels, and this phenomenon was accompanied by decreased CEC. In patients with CAD, the level of HDL-C cannot reflect HDL function. The impaired correlation between HDL-C and CEC is possibly due to an inflammation-induced HDL subclass remodeling. These hypothesis-generating data suggest that hsCRP levels, a marker of acute inflammation, may associate with HDL dysfunction in ACS subjects. Due to the design limited to be correlative in nature, not permitting causal inference and a larger, strictly designed study is still needed.

Citing Articles

Epigenome-wide mediation analysis of the relationship between psychosocial stress and cardiometabolic risk factors in the Health and Retirement Study (HRS).

Opsasnick L, Zhao W, Ratliff S, Du J, Faul J, Schmitz L Clin Epigenetics. 2024; 16(1):180.

PMID: 39695878 PMC: 11656575. DOI: 10.1186/s13148-024-01799-4.


Triglyceride-glucose Index as a Valuable Marker to Predict Severity of Coronary Artery Disease: A Retrospective Cohort Study.

Geng X, Zhang X, Li X, Zhong C, Hou M Clin Appl Thromb Hemost. 2024; 30:10760296241234320.

PMID: 38444211 PMC: 10916460. DOI: 10.1177/10760296241234320.


Targeting inflammation in atherosclerosis: overview, strategy and directions.

Waksman R, Merdler I, Case B, Waksman O, Porto I EuroIntervention. 2024; 20(1):32-44.

PMID: 38165117 PMC: 10756224. DOI: 10.4244/EIJ-D-23-00606.


Seasonal Factors Are Associated with Activities of Enzymes Involved in High-Density Lipoprotein Metabolism among Pregnant Females in Ghana.

Hong B, Zheng J, Romo E, Agus J, Tang X, Arnold C Curr Dev Nutr. 2023; 7(12):102041.

PMID: 38130330 PMC: 10733676. DOI: 10.1016/j.cdnut.2023.102041.


Associations between neighborhood socioeconomic deprivation, IFNγ, and high-density lipoprotein particle size: Data from the Washington, D.C. cardiovascular health and needs assessment.

Ortiz-Whittingham L, Baumer Y, Pang A, Sampson M, Baez A, Rose R Psychoneuroendocrinology. 2023; 157:106346.

PMID: 37651859 PMC: 10543547. DOI: 10.1016/j.psyneuen.2023.106346.


References
1.
Boden W, Probstfield J, Anderson T, Chaitman B, Desvignes-Nickens P, Koprowicz K . Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011; 365(24):2255-67. DOI: 10.1056/NEJMoa1107579. View

2.
Davidson W, Heink A, Sexmith H, Melchior J, Gordon S, Kuklenyik Z . The effects of apolipoprotein B depletion on HDL subspecies composition and function. J Lipid Res. 2016; 57(4):674-86. PMC: 4808776. DOI: 10.1194/jlr.M066613. View

3.
Harbaum L, Ghataorhe P, Wharton J, Jimenez B, Howard L, Gibbs J . Reduced plasma levels of small HDL particles transporting fibrinolytic proteins in pulmonary arterial hypertension. Thorax. 2018; 74(4):380-389. PMC: 6475111. DOI: 10.1136/thoraxjnl-2018-212144. View

4.
Ridker P, MacFadyen J, Everett B, Libby P, Thuren T, Glynn R . Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2017; 391(10118):319-328. DOI: 10.1016/S0140-6736(17)32814-3. View

5.
Gordon D, Probstfield J, Garrison R, Neaton J, CASTELLI W, Knoke J . High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989; 79(1):8-15. DOI: 10.1161/01.cir.79.1.8. View